Soligenix has signed an exclusive option agreement with Silk Road Therapeutics for the right to acquire Pentoxifylline (PTX) topical formulation intended to treat mucocutaneous ulcers in Behçet’s disease (BD) patients.
The firms did not divulge the terms of the deal.
Go deeper with GlobalData
BD is a rare multisystem inflammatory vasculitis, which currently has no treatment.
The disease is characterised by severe recurrent ulcers in the oral mucosa, skin, genitalia and eyes.
It is estimated to impact around 18,000 people in the US and 80,000 in Europe, while 1,000,000 people are living with the disease across the globe.
See Also:
Soligenix reported that PTX was found to be more effective than colchicine in a Phase II proof-of-concept (POC) trial. BD patients were randomised to receive either standard-of-care colchicine therapy or colchicine in combination with topical PTX.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataPatients applied the PTX mucoadhesive gel four times a day for up to 14 days for treating current mouth ulcers. They also used their standard colchicine regimen.
It was found that 83% of patients treated with PTX had index ulcer area shrinkage by day two, as against 19% of patients treated with only colchicine.
Meanwhile, pain scores were also reported to be reduced in patients receiving PTX. No serious adverse events were observed among the patients.
Soligenix president and CEO Christopher Schaber said: “The novel muco-adherent topical formulation of PTX has the potential to fill a significant void in the current treatment armamentarium for BD, where a clear unmet medical need exists.
“General agreement amongst treating physicians is that current front-line treatment/management options, such as oral and topical steroids, are largely ineffective and have a number of potentially significant safety issues when used long-term.
“When transitioning to the more effective therapies, like biologics such as adalimumab and apremilast, the only approved treatment in BD, these longer-term safety concerns persist and are associated with a much higher financial burden to patients and/or payers in treating this lifelong condition.”
